Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + thalidomide + dexamethasone (CaTD) in relapsed/refractory multiple myeloma
KCT0003393Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib, thalidomide, dexamethasone in multiple myeloma (MM), sponsored by Samsung Medical Center. Started Mar 2019; status: completed.
02
Drugs
carfilzomibthalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0003393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003393.